• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

UAE approves Sinopharm’s protein-based vaccine

ExpressPharmaDecember 29, 2021

Tag: UAE , Sinopharm , Vaccine

The United Arab Emirates (UAE) has approved emergency use of Sinopharm’s protein-based COVID-19 vaccine and it will be available to the public as a booster dose starting January 2022, the health ministry said.

The vaccine will be produced and distributed by a joint venture between the UAE’s Group 42 and China National Biotec Group (CNBG), a unit of China National Pharmaceutical Group (Sinopharm), the ministry said in a statement on state media yesterday.

The approval came following a UAE-based study that included individuals who were previously vaccinated with two doses of Sinopharm CNBG’s inactivated vaccine, the ministry added.

Previous:Stopping dementia at the nose with combination of rifampicin and resveratrol

Next:Chinese mainland reports 182 locally transmitted COVID-19 cases

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

UAE approves Sinopharm’s protein-based vaccine | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Hualan inactivated flu vaccine

Hualan inactivated flu vaccine
High-quality Influenza Vaccine (Split virion), inactivated

High-quality Influenza Vaccine (Split virion), inactivated
Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live

Poliomyelitis Vaccine Type I Type III in Dragee Candy (Human Diploid Cell), Live
Influenza Vaccine by Hualan Bio

Influenza Vaccine by Hualan Bio
H7N9 Inactivated Influenza Vaccine

H7N9 Inactivated Influenza Vaccine
Hualan Bio Meningococcal Polysaccharide Vaccine Group ACYW135

Hualan Bio Meningococcal Polysaccharide Vaccine Group ACYW135
2024-2025 quadrivalent/trivalent flu vaccine

2024-2025 quadrivalent/trivalent flu vaccine
Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral

Poliomyelitis (Live) Vaccine Type I Type III (Human Diploid Cell), Oral
High-standard and safety Influenza Vaccine (Split virion), inactivated

High-standard and safety Influenza Vaccine (Split virion), inactivated
Intranasal spray device, 100mcl, for vaccine delivery

Intranasal spray device, 100mcl, for vaccine delivery

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service